SCHEMBL6206600

SCHEMBL6206600

O=C(c1cccc2c1OCO2)c1cccc2c1OCO2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.44
GSK3B P49841 1/20 0.44
KDM4C Q9H3R0 1/20 0.43
MAOB P27338 3/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
CTNNB1 P35222 3/20 0.41
WNT3A P56704 3/20 0.41
MAPK14 Q16539 1/20 0.41
MT-CO2 P00403 1/20 0.40
MGAM O43451 1/20 0.40
AMY1A P0DUB6 1/20 0.40
GAA P10253 1/20 0.40
SI P14410 1/20 0.40
MGAM2 Q2M2H8 1/20 0.40
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29514911 0.88 AKR1C3 (0.47) ABCG2KDM4CMAOBALDH1A1CTNNB1
SCHEMBL7002428 0.88 AKR1C3 (0.47) ABCG2KDM4CMAOBALDH1A1CTNNB1
SCHEMBL29442138 0.86 KDM4C (0.52) ABCG2GSK3BKDM4CMAOBPOLB
SCHEMBL340702 0.86 KDM4C (0.52) ABCG2GSK3BKDM4CMAOBPOLB
SCHEMBL23079145 0.85 GSK3B (0.42) ABCG2GSK3BKDM4CMAOBPOLB
SCHEMBL1720148 0.85 PARP1 (0.54) POLBMAPK1KDM4EALDH1A1LMNA
SCHEMBL341608 0.85 GSK3B (0.42) ABCG2GSK3BKDM4CMAOBPOLB
SCHEMBL340356 0.85 KDM4E (0.44) ABCG2GSK3BKDM4CMAOBKDM4E
SCHEMBL29625406 0.85 PARP1 (0.54) POLBMAPK1KDM4EALDH1A1LMNA
Hydrochloric Acid SCHEMBL9236405 0.85 KDM4C (0.51) ABCG2GSK3BKDM4CMAOBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1593683-A2 Dihydro-2,3-Benzodiazepine derivatives ELI LILLY AND COMPANY (US) 2005-11-09 EP disclosed
EP-1157992-B1 Dihydro-2,3-Benzodiazepine derivatives LILLY CO ELI (US) 2005-08-24 EP disclosed
EP-0699678-B1 Crystalline form of dihydro-2,3-benzodiazepine derivative LILLY CO ELI (US) 2004-03-24 EP disclosed
EP-0771198-B1 DIHYDRO-2,3-BENZODIAZEPINE DERIVATIVES LILLY CO ELI (US) 2002-02-06 EP disclosed
US-6329364-B1 COMPOUND WITH CRYSTAL STRUCTURE FOR TREATMENT OF NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY 2001-12-11 US disclosed
EP-1157992-A1 Dihydro-2,3-Benzodiazepine derivatives ELI LILLY AND COMPANY (US) 2001-11-28 EP disclosed
CN-1073996-C Crystalline form of dihydro-2,3-benzodiazepine derivative LILLY CO ELI (US) 2001-10-31 CN disclosed
CN-1073995-C Physical form of dihydro-2,3-benzodiazepine derivative LILLY CO ELI (US) 2001-10-31 CN disclosed
US-6288057-B1 AMPA ANTAGONIST; NERVOUS SYSTEM, BRAIN, AND PSYCHOLOGICAL DISORDERS ELI LILLY AND COMPANY 2001-09-11 US disclosed
EP-0699676-B1 Physical form of dihidro-2,3-benzodiazepine derivative LILLY CO ELI (US) 2001-02-07 EP disclosed
US-5795886-A ANTICONVULSANTS ELI LILLY AND COMPANY (US) 1998-08-18 US disclosed
CN-1128264-A Crystalline form of dihydro-2,3-benzodiazepine derivative LILLY CO ELI (US) 1996-08-07 CN disclosed
CN-1122338-A Physical form of dihydro-2,3-benzodiazepine derivative LILLY CO ELI (US) 1996-05-15 CN disclosed
WO-1996006606-A1 DIHYDRO-2,3-BENZODIAZEPINE DERIVATIVES ELI LILLY AND COMPANY (US) 1996-03-07 WO disclosed
EP-0699678-A1 Crystalline form of dihydro-2,3-benzodiazepine derivative ELI LILLY AND COMPANY (US) 1996-03-06 EP disclosed
EP-0699676-A1 Physical form of dihidro-2,3-benzodiazepine derivative ELI LILLY AND COMPANY (US) 1996-03-06 EP disclosed